BVS Earnings Prediction
The chart below shows how BVS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BVS sees a +9.83% change in stock price 10 days leading up to the earnings, and a +9.74% change 10 days following the report. On the earnings day itself, the stock moves by -1.33%. This data can give you a slight idea of what to expect for the next quarter's release.
BVS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
138.96M
15.04%
-8.10%
Gross Margin
65.83%
--
-1.99%
Operating Margin
6.53%
--
-45.58%
Net Margin
-3.90%
--
-81.64%
EPS
-0.07
-41.67%
-81.08%
No Data Available
BVS Earnings Analysis
Bioventus Inc. Class A Common Stock Corporation (BVS.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: We delivered a strong quarter with revenue of $139 million, increasing 15% compared to the prior year.
Consistent Double-Digit Growth: We maintained strong momentum across all three businesses with double digit growth in both pain treatments and surgical solutions for the fourth consecutive quarter.
EBITDA Growth Achievement: Adjusted EBITDA of over $24 million increased by $2 million and represented an 8% increase compared to the prior year.
Adjusted EBITDA Increase: Year-to-date adjusted EBITDA is up 21% compared to the prior year.
Cash Position Improvement: We ended the quarter with $43 million of cash on hand, an increase of $11 million for the quarter.
Negative
Revenue Growth Decline: Revenue of $139 million increased 15% compared to the prior year, but this growth rate is lower than previous quarters.
Adjusted Gross Margin Decline: Adjusted gross margin of 75% was comparable to last year, down 10 basis points, indicating a slight decline in profitability.
Increased Operating Expenses: Adjusted operating expenses rose by nearly $13 million compared to the prior year, reflecting increased investments in strategic growth areas.
BGS Growth Slowdown: The company expects a slowdown in growth in the BGS business due to earlier actions taken to delay adding new distributors, which may impact future revenue.
Cash Flow Pressures: Operating cash flow represented an inflow of $10 million despite the payment of more than $9 million during the quarter to settle shareholder litigation, indicating cash flow pressures.
BVS FAQs
How does BVS typically perform around its earnings report dates?
Is Bioventus Inc. (BVS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BVS Earning Call Sentiment
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BVS.O
1.38%Positive
The earnings call reveals strong financial performance with 15% revenue growth, improved adjusted EBITDA, and positive EPS guidance. Despite challenges like regulatory issues and supply chain slowdowns, the company remains optimistic about double-digit growth and margin improvement. The Q&A indicates confidence in overcoming short-term issues, and the increased revenue guidance further supports a positive outlook. The settlement payment and improved cash position suggest better financial health. Overall, the sentiment is positive, leading to an expected stock price increase of 2% to 8% over the next two weeks.